Landos Biopharma (LABP) PT Lowered to $30 at Jefferies

Jefferies analyst Chris Howerton lowered the price target on Landos Biopharma (NASDAQ: LABP) to $30.00 (from $32.00) while maintaining a Buy rating.

The analyst commented, "Following recent leadership transition with new Chairman and interim CEO, Co announced to strategically re-prioritize pipeline optimizing clinical development and capital allocation. As a result, Co expects to be focused on omilancor, NX-13 and LABP-104, and plans to start a Ph2b vs. Ph3 for omilancor in UC and reassess Ph2 powering in CD. We see this a sensible move and update our PT to $30 (vs. prev. $32) to reflect new pipline plan. We maintain Buy rating."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'